Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia
Phase of Trial: Phase I/II
Latest Information Update: 16 May 2019
Price : $35 *
At a glance
- Drugs Curcumin (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 19 Oct 2017 Status changed from recruiting to completed.
- 21 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.